Therapeutic polypeptides based on HBV core 18-27 epitope can induce CD8+ CTL-mediated cytotoxicity in HLA-A2+ human PBMCs

Table 3 Percentages of specific targets lysis by HLA-A2⁺ effec-tor CTLs induced by PBMCs from healthy donors with differ-ent peptide antigens (mean ± SD, n = 27)

E/T ratios	Percentage of specific cell lysis (%)
	Peptide1d	Peptide2d	Peptide3db	Irrelevant controla	Negative controls
12.5	22.7 ± 5.3	21.7 ± 6.1	36.1 ± 7.7	3.7 ± 0.7	3.5 ± 0.7
25	29.3 ± 6.5	28.6 ± 6.3	41.4 ± 9.1	5.7 ± 0.7	3.7 ± 0.7
50	33.5 ± 7.1	33.9 ± 8.2	52.3 ± 12.5	7.3 ± 0.9	6.4 ± 0.9
100	37.2 ± 11.2	36.8 ± 10.9	68.4 ± 14.7	7.4 ± 1.1	8.7 ± 1.3

^aP > 0.05 vs negative control,

^bP < 0.01 vs peptide1 and 2 groups,

^dP < 0.01 vs negative control.